As the COVID-19 epidemic waned and companies got back to business as usual, SmartTRAK continued to keep you informed of everything that transpired in the MedTech industry in 2022. Here are SmartTRAK's Top 10 blog posts of the past year that garnered the most attention from you and your colleagues, plus 4 bonus posts, because at SmartTRAK we always strive to deliver more than what's expected!

As the leading provider of real-time market data and analysis for the orthopedic, wound, regenerative medicine and neuro therapies markets, SmartTRAK is uniquely suited to make you the expert on all the latest developments. Our knowledgeable analysts covered a lot of ground, everything from breaking medical device event coverage to interviews with some of the industry's top thought leaders.

Medtronic: The Future of Neuromodulation in 2022 and Beyond
by Anne Staylor

Dave Anderson, Medtronic’s President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss the Company, the pandemic and the future of neuromodulation in a wide-ranging interview with SmartTRAK.

SmartTRAK interviews Dr. Pascal-André Vendittoli to learn more about the Personalized Arthroplasty Society and this year’s annual meeting.

Dr. Vendittoli explains the difference between mechanical and kinematic alignment, what he looks for in total joint computer-assisted surgery systems and why he thinks personalized arthroplasty is the future of joint surgery. To find out more, listen to the SmartTRAK interview with Dr. Vendittoli in the video below (14:56 min). A link to download the transcript of the complete interview is also provided below.

SmartTRAK interviews Oxford Performance Materials CEO Scott DeFelice to learn more about the company’s PEKK-based materials solutions in orthopedics.

In an interview with   SmartTRAK, Oxford Performance Materials’ (OPM) CEO Scott DeFelice explains the history of his company, the difference between PEKK, PEEK and titanium-based implants and the Company’s future plans in the orthopedic space.

To find out more, including OPM’s plan to expand into the custom trauma market and its planned release of an all-polymer total knee, just click on the following video to listen to the full interview. (29:13 min).  A link to download a transcript of the complete interview is also provided below.

Headwinds persist for the Arthroscopic Technologies Market in Q322

With most of the major headwinds caused by COVID-19 in the rear-view mirror, the Arthroscopic Technologies (AT) Market showed growth in the third quarter with WW Arthroscopic Technologies revenues up +4.2% over Q321. The quarter saw a continued rise in procedural volumes globally that resulted in growth for the AT disposables market which trends with case volumes. On the capital side of the AT Market, capital spending and demand remained strong for items such as arthroscopic camera systems with new equipment purchases as well as an increasing need for replacement capital driving demand.

Among the many topics covered in detail in our comprehensive Q322 Arthroscopic Technologies Market Recap* are:

With the recent announcement that 3M is spinning off its Health Care division, SmartTRAK looks back at the evolution of 3M Health Care, its businesses today, the entry into Advanced Wound Care (AWC) and potential new opportunities for the new Health Care business.

3M, a large, diversified company with annual sales of $35.4B in 2021 announced earlier this year plans to spin-off its Health Care business into a new public company. Today, 3M markets thousands of products through four business groups: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. Post-spin-off, 3M will continue as a leading global material science innovator, while the new stand-alone business will seek to become a global diversified healthcare company focused on wound care, healthcare IT, oral care and biopharma filtration.


Among the many topics covered in this fascinating article are:

SmartTRAK reports that Q322 Spine Market performance drove a lack of consensus on operational performance metrics, while a shifting procedural landscape offered new product opportunities for small and mid-tier players, driving competitive pressure.

Among the many topics covered in detail in our comprehensive Q322 Spine Market Recap* are:

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Despite declining OUS results, the US Trauma Market experienced healthy growth attributed to adoption of new products.

While OUS results declined in Q322 due to foreign currency headwinds and China’s value-based pricing, the US drove the overall market through product penetration and easier comps due to the Q321 COVID waves that impacted procedural volumes last year. Companies posted healthy US growth, attributing new products for driving growth, with plans for additional launches in Q4 and 2023.

Among the many topics covered in detail in our comprehensive Q322 Trauma Market Recap* are: